HAUGEN JANET BRUTSCHEA 4

What Happened

• Janet Brutschea Haugen, a director of West Pharmaceutical Services, was granted 791 restricted stock units (RSUs) on May 4, 2026. The grant is reported as an award/acquisition (code A) at a reported price of $0.00 (total $0). This is a compensatory director award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-04; Form 4 filed 2026-05-06 (appears timely within the usual 2-business-day reporting window).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 791 RSUs; reported acquisition price: $0.00 (no cash paid).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Footnote: RSUs will vest in full on the date of the next annual shareholder meeting and will be distributable under the Deferred Compensation Plan for Outside Directors.

Context

• RSU grants to outside directors are routine compensation and do not reflect an open-market purchase or sale. The award has no immediate cash value until vesting/distribution; tax and economic exposure will depend on the Deferred Compensation Plan terms and the vesting/distribution timing.